Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT

·5 min read
Xcelerate Inc.
Xcelerate Inc.

Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT

CEO Mike O’Shea of Xcelerate, Inc., a development stage startup focused on the development of cutting-edge medtech applications, met with SmallCapVoice.com  to discuss the recent appointment of a new board member and the acquisition of a rather sizeable patent portfolio.
CEO Mike O’Shea of Xcelerate, Inc., a development stage startup focused on the development of cutting-edge medtech applications, met with SmallCapVoice.com to discuss the recent appointment of a new board member and the acquisition of a rather sizeable patent portfolio.

AUSTIN, Texas, May 23, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O’Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT, “Xcelerate” or “The Company”), and Jon Wilken, president and CEO of HS Pharmaceuticals, LLC.

CEO Mike O’Shea of Xcelerate, Inc., a development stage startup focused on the development of cutting-edge medtech applications, met with SmallCapVoice.com to discuss the recent appointment of a new board member and the acquisition of a rather sizeable patent portfolio.

This acquisition expands upon The Company’s mission of acquiring innovation in the engineering and patent stages of production for further development and commercialization within the medical industry.

O’Shea was joined by Jon Wilken, President and CEO of HS Pharmaceuticals, LLC. They opened up about his new role as a board member for Xcelerate and what has led up to the acquisition to this point.

Wilken spent more than 30 years in the supermarket retail industry before leaving the business in 2002. He also spent more than 10 years teaching entrepreneurial leadership at Clemson University. Venturing into the biopharmaceuticals industry, he then left academia and accepted the role as CEO and president of HS Pharmaceuticals, where he led the charge in the discovery of many early-stage drugs and immunotherapies.

As CEO of HS Pharmaceuticals, Wilken would focus on innovative and breakthrough treatments for chronic wounds and conditions that affect the human body on a molecular level, creating dermatological products for chronic wounds, burns, and drug-resistant infections, as well as patented formulas for some of the most game-changing cosmetics and beauty products on the market.

Throughout the years, the company would also focus on oncology, autoimmune therapies, cancer treatment and bone regeneration for both man and animal – many of which would be developed in collaboration with scientists at the Lakehead and Cambridge Universities.

In a previous press release, O’Shea stated that "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world-renowned scientists and universities, and we are excited to take this amazing intellectual property to the next level."

"The Board and I welcome Jon,” he continued, “and look forward to collaborating with him on the various projects and, more especially, assisting in assimilating the recently acquired patent portfolio into our business plan. Jon has spent years coordinating the development of these patents and coordinating the efforts of various research scientists and universities."

For the last 2 years, both companies have been in negotiation, making sure the climate was suitable when merging HS Pharmaceuticals into the fold of Xcelerate and its growing list of revolutionary technologies.

Since announcing that it had signed a purchase agreement to acquire a global portfolio of patents, patents pending, and technology licenses from HS Pharmaceuticals LLC, The Company would go on to add a number of patents and patents pending across the U.S., Canada and Eurasia, which can be found here.

“We're excited about this relationship with Mike and his team,” states Wilken. “We're looking forward to our scientists, our research people, our PhDs working with the people that Mike has on board. It's going to be a great collaboration.”

Xcelerate plans on taking the research conducted by HS Pharmaceuticals and its entire portfolio of patents to the next level. Together, the companies have devised a plan that is expected to become of great interest to major pharmaceutical houses across the industry.

To hear the interview in its entirety and to learn about what sets this acquisition apart from the rest, click here https://www.smallcapvoice.com/may-interview-xcelerate-xcrt/.

About Xcelerate, Inc.

Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.

Xcelerate has also recently acquired a 51% ownership interest in AfiyaSasa Africa, LLC a start-up medical technology and virtual health company, recently founded by Dr. Dilan Ellegala and Doyle Word. This technology is centered around patented and patent pending software that uses and incorporates artificial intelligence ("AI") and Augmented Reality ("AR") licensed from AdviNOW.

For more information, visit the company's website at http://Xcelerate.Global/

SAFE HARBOR

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

Xcelerate Contact

Info@Xcelerate.Global

SOURCE: Xcelerate, Inc.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting